Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Germany; Cancer Institute, University College London, United Kingdom; Francis Crick Institute, London
Eli Lilly and Company, Bracknell
Eli Lilly and Company, Indianapolis, IN
TechDataServices, LLC, King of Prussia, PA
Eli Lilly and Company, Bad Homburg
LOXO@Lilly, Indianapolis, IN
Eli Lilly and Company, Indianapolis, IN
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford
Vol. 109 No. 6 (2024): June, 2024